US1598641074 - Common Stock

Taking everything into account, **CRL** scores **5** out of 10 in our fundamental rating. **CRL** was compared to 61 industry peers in the **Life Sciences Tools & Services** industry. While **CRL** has a great profitability rating, there are quite some concerns on its financial health. **CRL** has a decent growth rate and is not valued too expensively.

In the past year **CRL** was profitable.

In the past 5 years **CRL** always reported a positive cash flow from operatings.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 5.79% | ||

ROE | 13.2% | ||

ROIC | 7.4% |

ROA(3y)5.92%

ROA(5y)5.95%

ROE(3y)14.99%

ROE(5y)15.52%

ROIC(3y)8.07%

ROIC(5y)7.97%

The **Profit Margin** of **CRL** (**11.49%**) is better than **78.69%** of its industry peers.

The **Operating Margin** of **CRL** (**15.82%**) is better than **80.33%** of its industry peers.

Looking at the **Gross Margin**, with a value of **36.89%**, **CRL** is doing worse than **60.66%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 15.82% | ||

PM (TTM) | 11.49% | ||

GM | 36.89% |

OM growth 3Y0.93%

OM growth 5Y0.35%

PM growth 3Y-2.65%

PM growth 5Y2.84%

GM growth 3Y0.29%

GM growth 5Y-0.02%

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so **CRL** is destroying value.

The number of shares outstanding for **CRL** has been increased compared to 1 year ago.

Compared to 5 years ago, **CRL** has more shares outstanding

The debt/assets ratio for **CRL** has been reduced compared to a year ago.

The Debt to FCF ratio of **CRL** is **7.26**, which is on the high side as it means it would take **CRL**, **7.26** years of fcf income to pay off all of its debts.

Looking at the **Debt to FCF ratio**, with a value of **7.26**, **CRL** is in the better half of the industry, outperforming **68.85%** of the companies in the same industry.

Looking at the **Debt to Equity ratio**, with a value of **0.74**, **CRL** is doing worse than **78.69%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.74 | ||

Debt/FCF | 7.26 | ||

Altman-Z | 2.82 |

ROIC/WACC0.64

WACC11.56%

Looking at the **Current ratio**, with a value of **1.52**, **CRL** is doing worse than **85.25%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.52 | ||

Quick Ratio | 1.16 |

The earnings per share for **CRL** have decreased by **-4.31%** in the last year.

The **Earnings Per Share** has been growing by **12.09%** on average over the past years. This is quite good.

The **Revenue** has been growing slightly by **3.86%** in the past year.

Measured over the past years, **CRL** shows a quite strong growth in **Revenue**. The Revenue has been growing by **12.75%** on average per year.

EPS 1Y (TTM)-4.31%

EPS 3Y9.37%

EPS 5Y12.09%

EPS growth Q2Q-17.45%

Revenue 1Y (TTM)3.86%

Revenue growth 3Y12.2%

Revenue growth 5Y12.75%

Revenue growth Q2Q-7.85%

EPS Next Y2.51%

EPS Next 2Y7.82%

EPS Next 3Y10.68%

EPS Next 5Y14.63%

Revenue Next Year3.19%

Revenue Next 2Y5.44%

Revenue Next 3Y6.11%

Revenue Next 5Y7.01%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

Based on the **Price/Earnings** ratio of **23.26**, the valuation of **CRL** can be described as rather expensive.

Compared to the rest of the industry, the **Price/Earnings** ratio of **CRL** indicates a rather cheap valuation: **CRL** is cheaper than 90.16% of the companies listed in the same industry.

When comparing the **Price/Earnings** ratio of **CRL** to the average of the S&P500 Index (**26.35**), we can say **CRL** is valued inline with the index average.

A **Price/Forward Earnings** ratio of **22.69** indicates a rather expensive valuation of **CRL**.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **CRL** indicates a rather cheap valuation: **CRL** is cheaper than 88.52% of the companies listed in the same industry.

When comparing the **Price/Forward Earnings** ratio of **CRL** to the average of the S&P500 Index (**21.63**), we can say **CRL** is valued inline with the index average.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 23.26 | ||

Fwd PE | 22.69 |

93.44% of the companies in the same industry are more expensive than **CRL**, based on the **Enterprise Value to EBITDA** ratio.

Based on the **Price/Free Cash Flow** ratio, **CRL** is valued a bit cheaper than the industry average as 75.41% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 34.78 | ||

EV/EBITDA | 15.55 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates **CRL** does not grow enough to justify the current Price/Earnings ratio.

The decent profitability rating of **CRL** may justify a higher PE ratio.

PEG (NY)9.27

PEG (5Y)1.92

EPS Next 2Y7.82%

EPS Next 3Y10.68%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**CHARLES RIVER LABORATORIES**

NYSE:CRL (2/23/2024, 7:04:00 PM)

After market: 247.71 0 (0%)**247.71**

**+0.81 (+0.33%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap12.71B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 23.26 | ||

Fwd PE | 22.69 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)9.27

PEG (5Y)1.92

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 5.79% | ||

ROE | 13.2% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 15.82% | ||

PM (TTM) | 11.49% | ||

GM | 36.89% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.5

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.74 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.52 | ||

Quick Ratio | 1.16 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-4.31%

EPS 3Y9.37%

EPS 5Y

EPS growth Q2Q

EPS Next Y2.51%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)3.86%

Revenue growth 3Y12.2%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y